UPDATED May 18, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
VTSI | US$10.11 | -39.5% | 36.3% | US$112.3m | US$17.50 | PE16.8x | E23.7% | n/a | Capital Goods | ||
ASLE | US$7.74 | -2.8% | -52.3% | US$410.3m | US$10.50 | PE578.7x | E106.1% | n/a | Capital Goods | ||
AUNA | US$8.72 | -8.0% | n/a | US$644.6m | US$16.05 | PB1.6x | E45.4% | n/a | Healthcare | ||
YSG | US$4.50 | -0.9% | 1.2% | US$482.6m | US$4.35 | PS1x | E120.5% | n/a | Household | ||
OPNT | US$20.65 | -1.3% | -22.3% | US$108.8m | US$21.50 | PS4.9x | E62.6% | n/a | Pharmaceuticals & Biotech | ||
ECOR | US$7.00 | 2.3% | 16.5% | US$42.0m | US$23.16 | PS2x | E67.0% | n/a | Healthcare | ||
AXSM | US$76.54 | 5.6% | 1.1% | US$3.6b | US$123.56 | PS14.5x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$220.06 | 7.2% | -20.4% | US$4.7b | US$363.86 | PB5.5x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
ARQT | US$9.20 | 17.3% | -2.9% | US$1.1b | US$18.83 | PS10x | E65.9% | n/a | Pharmaceuticals & Biotech | ||
HRMY | US$29.03 | -3.7% | -17.1% | US$1.6b | US$42.25 | PE12x | E28.4% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.95 | 4.8% | -59.9% | US$234.7m | US$9.25 | PB2.1x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
INNV | US$3.70 | -9.3% | -45.9% | US$503.2m | US$6.00 | PB1.8x | E123.5% | n/a | Healthcare | ||
ARDX | US$7.81 | 0.5% | 120.0% | US$1.8b | US$13.83 | PS11.5x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
IMAX | US$16.96 | 2.0% | -10.3% | US$892.5m | US$22.25 | PE34.1x | E27.3% | n/a | Media | ||
COMP | US$4.30 | 10.3% | 5.7% | US$2.1b | US$4.15 | PB6.4x | E86.0% | n/a | Real Estate Management and Development | ||
WULF | US$1.95 | -12.6% | 25.0% | US$649.7m | US$3.62 | PS6.5x | E146.5% | n/a | Software | ||
IRWD | US$6.48 | -7.4% | -38.1% | US$1.0b | US$16.33 | PS2.5x | E76.2% | n/a | Pharmaceuticals & Biotech | ||
GAME | US$1.36 | -6.5% | -68.7% | US$41.2m | US$5.00 | PB2.2x | E100.9% | n/a | Media | ||
SLNO | US$46.16 | 2.6% | 853.7% | US$1.7b | US$68.14 | PB11.7x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
EOLS | US$13.59 | 6.6% | 37.4% | US$850.9m | US$22.29 | PS3.9x | E66.4% | n/a | Pharmaceuticals & Biotech | ||
ITCI | US$65.00 | 0.06% | 4.1% | US$6.9b | US$90.60 | PS13.4x | E60.5% | n/a | Pharmaceuticals & Biotech | ||
TTI | US$4.21 | 4.7% | 53.1% | US$552.1m | US$7.42 | PE27.1x | E43.3% | n/a | Energy | ||
FSI | US$2.15 | 3.9% | -28.3% | US$26.8m | US$5.00 | PE11.4x | E39.8% | 0% | Materials | ||
SNCY | US$10.75 | -6.7% | -40.2% | US$566.1m | US$18.17 | PE8.2x | E24.8% | n/a | Transportation |